Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

22 september 2026 bijgewerkt door: TearSolutions, Inc.

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep 4 μM Ophthalmic Solution in Subjects With Neurotrophic Keratitis

Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.

Studie Overzicht

Gedetailleerde beschrijving

The study will compare Lacripep 4 μM Ophthalmic Solution to vehicle ophthalmic solution for the treatment of Stage 1 neurotrophic keratitis (NK). Approximately 54 subjects will be enrolled and will enter a 2-week run-in period with open-label vehicle ophthalmic solution. At Visit 2 (Day 1; Baseline/Randomization), eligible subjects will be randomized to either Lacripep 4 μM Ophthalmic Solution or vehicle ophthalmic solution. Subjects will dose three times a day (TID) in both eyes (OU) for 8 weeks, with clinic visits at Week 2, Week 4, and Week 8.

A central reading center will assess study images to ensure objective, standardized, and unbiased grading.

At the Week 8 visit, subjects will be assigned to open-label treatment with Lacripep 4 μM Ophthalmic Solution for 4 weeks, through Week 12. The initiation of 4 weeks of open-label active treatment is designed to explore the potential effects of both a shorter and a longer treatment period: i.e., 4 weeks of active treatment for subjects originally randomized to vehicle ophthalmic solution, and 12 total weeks of active treatment for subjects originally randomized to Lacripep 4 μM Ophthalmic Solution. Subjects will continue to dose TID in both eyes.

All Week 1-8 treatment assignments will remain masked through database lock.

Studietype

Ingrijpend

Inschrijving (Geschat)

54

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Florida
      • Tampa, Florida, Verenigde Staten, 33612
        • Werving
        • University of South Florida
        • Contact:
    • Indiana
      • Carmel, Indiana, Verenigde Staten, 46032
    • Massachusetts
      • Russells Mills, Massachusetts, Verenigde Staten, 02747
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55431
        • Werving
        • Minnesota Eye Consultants
        • Contact:
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63131
    • New York
      • New York, New York, Verenigde Staten, 10017

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Subjects who meet all the following inclusion criteria at Visit 1 (Screening) will be eligible to participate in the study.

  1. Are ≥18 years of age.

  2. Provide informed consent before any study-related procedures are performed.

  3. Are willing and able to comply with study procedures and the study schedule.

  4. Female subjects must either be incapable of pregnancy or must use an effective method of birth control for the duration of the study. Female subjects of childbearing potential must have a negative pregnancy test and not be nursing.

  5. Have all of the following in at least one eye:

    1. Stage 1 NK as defined by:

      • Grade 3 cCFS using the National Eye Institute (NEI) scale (0-3 in one-point increments).
      • Corneal sensitivity ≤4 cm in the central zone, as measured by Cochet-Bonnet aesthesiometer.
    2. BCDVA +0.2 to +1.0 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent 20/32 to 20/200).

    3. IOP ≤21 mmHg.

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria at Visit 1 (Screening) will not be eligible to participate in the study. Ocular criteria apply to each eye independently, unless otherwise noted.

  1. Have received prior treatment with Lacripep Ophthalmic Solution or Oxervate® (cenegermin-bkbj) Ophthalmic Solution within 6 months prior to Visit 1 (Screening) and failed to demonstrate a clinically meaningful response, as determined by the Investigator.
  2. Have participated in a NK study within 90 days prior to Visit 1 (Screening).
  3. Have participated in any other clinical study or used an investigational agent within 30 days prior to Screening or plans to participate in another clinical study at any time during the conduct of this study.
  4. Have a glycated hemoglobin (HbA1c) score >9% within 90 days prior to Visit 1 (Screening).
  5. Have a history of or current conditions that may confound the study data; such conditions include but are not limited to ocular cicatricial pemphigoid, graft versus host disease, neuromyelitis optica, Stevens-Johnson syndrome, and Salzmann's nodular degeneration.
  6. Have an unstable history of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis expected during the study period) or chronic conjunctivitis and/or keratitis other than dry eye disease.
  7. Have been diagnosed with glaucoma or are a glaucoma suspect who requires or may require treatment during the study.
  8. Have, in the opinion of the Investigator, evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.
  9. Have any intraocular inflammation (Tyndall score >0).
  10. Have, in the opinion of the Investigator, severe vision loss due to retinal disease, with no potential for visual improvement.
  11. Have an eyelid abnormality that may alter eyelid function; such abnormalities include but are not limited to blepharospasm, cerebrovascular accident, entropion, ectropion, and floppy lid syndrome.
  12. Have punctal occlusion or punctal plugs that will not be maintained during the study period.
  13. Have had any corneal surface procedure within 90 days prior to Visit 1 (Screening). This includes laser-assisted in situ keratomileusis (LASIK), phototherapeutic or photorefractive keratectomy (PTK or PRK), radial keratotomy (RK), small-incision lenticule extraction (SMILE), penetrating keratoplasty (PK), automated lamellar keratoplasty (ALK), deep anterior lamellar keratoplasty (DALK), Descemet membrane endothelial keratoplasty (DMEK), Descemet stripping endothelial keratoplasty (DSEK), superior limbic keratoconjunctivitis (SLK) surgery, and placement of any amniotic membrane.
  14. Have, in the opinion of the Investigator, NK that was induced by a neurosurgical procedure.
  15. Have undergone any other ocular surgery (including peripheral iridotomy (PI), laser iridotomy (LI) eyelid surgery and any surgical refractive procedures) within 90 days prior to Visit 1 (Screening) or expect to undergo ocular surgery during the study period.
  16. Have, in the opinion of the Investigator, history of viral corneal disease that resulted in significant corneal scarring.
  17. Have viral corneal disease without scarring that is considered unstable prior to Visit 1 (Screening), defined as discontinuation of topical ocular antiviral therapy or topical ocular steroid therapy within 2 weeks prior to Screening, or evidence of viral reactivation during the run-in period.
  18. Have received Botox (botulinum toxin) ocular injections to induce pharmacologic blepharoptosis within 45 days prior to Visit 1 (Screening).
  19. Have used any non-study issued eye drops or neurostimulators within 14 days prior to Visit 2 (Day 1; Baseline/Randomization).
  20. Anticipate a need to use therapeutic contact lenses or unwilling to discontinue wearing contact lenses for refractive correction during the study period.
  21. Have, in the opinion of the Investigator, an unstable medical condition that may confound the study data; such conditions include but are not limited to diabetes, thyroid disease, autoimmune disease, Parkinson's disease, and multiple sclerosis.
  22. Evidence of current drug or alcohol abuse or addiction, in the opinion of the Investigator.
  23. Are pregnant, nursing, or planning a pregnancy during the study period.
  24. Are an employee of a site directly involved in the management, administration, or support of the study or an immediate family member of the same.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Placebo-vergelijker: Voertuig

Vehicle ophthalmic solution

Experimenteel: Lacripep

Lacripep 4 μM Ophthalmic Solution

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Primary Efficacy
Tijdsspanne: Baseline to Week 8

Change from baseline in cCFS at Week 8 in Study Eye

Baseline to Week 8

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Secondary Efficacy
Tijdsspanne: Baseline to Week 8

Change from baseline in central corneal sensitivity at Week 8 in Study Eye

Baseline to Week 8

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Marc Odrich, MD, TearSolutions CMO

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 februari 2026

Primaire voltooiing (Geschat)

1 februari 2027

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

28 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

28 april 2026

Eerst geplaatst (Werkelijk)

6 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

22 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • TS-NK-001

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren